Sign up for the QMED & MD+DI Daily newsletter.
Tandem Sure Has Been Busy Lately. What’s Up with That?
MD+DI Managing Editor Omar Ford digs into the recent activity and explains what it means for Tandem and what it could mean for companies during the COVID-19 pandemic.
In the last few months, Tandem Diabetes Management has made an acquisition and signed deals with two of medtech's biggest powerhouses - Abbott Laboratories and Medtronic. But what does it all mean? MD+DI's Managing Editor Omar Ford tries to make sense of the companies recent momentum.
About the Author(s)
You May Also Like
Get Your Melons Checked at WalmartMar 4, 2024|3 Min Read
Medtech in a Minute: Integra's Bold Decision, and MoreMar 4, 2024|1 Min Read
Medtronic Won't Back Down but Axonics Stands Its GroundMar 4, 2024|1 Min Read
Empatica Launch Next-Gen FDA-Cleared Epilepsy WatchMar 1, 2024|2 Min Read